$Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant$

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant

Bibliographic Details
Main Authors:	Ashley McEwan, Omali Pitiyarachchi, Nicholas Viiala
Format:	Article
Language:	English
Published:	Wolters Kluwer 2020-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000379

Similar Items

Nelarabine in the Treatment of Refractory T-Cell Malignancies
by: Andrew M. Roecker, et al.
Published: (2010-01-01)

VENETOCLAX FOR RELAPSED ACUTE MYELOID LEUCEMIA AS A “BRIDGE FOR ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANT”: A CASE REPORT
by: A.P. Udo, et al.
Published: (2020-11-01)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
by: Maansi Joshi, et al.
Published: (2021-03-01)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
by: Leena T. Rahmat, et al.
Published: (2018-01-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
by: Elisabetta Zappone, et al.
Published: (2020-10-01)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
by: Vikram J. Premkumar, et al.
Published: (2021-01-01)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
by: Huber H, et al.
Published: (2017-02-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

Nelarabine Associated Myotoxicity and Rhabdomyolysis
by: Mahnur Haider, et al.
Published: (2015-01-01)

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab
by: Alla V Rudakova, et al.
Published: (2019-06-01)

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
by: Davids, Matthew S., et al.
Published: (2017)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
by: Nerea Báez-Gutiérrez, et al.
Published: (2021-08-01)

Refractory Autoimmune Cytopenias Treated With Venetoclax
by: Max J. Gordon, et al.
Published: (2019-06-01)

Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients
by: Joanne E. Davis, et al.
Published: (2021-09-01)

CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
by: Luca Castagna, et al.
Published: (2015-02-01)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
by: Harinder Gill, et al.
Published: (2020-05-01)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
by: Paul J. Hampel, et al.
Published: (2021-03-01)

Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax
by: Ching Soon Teoh, et al.
Published: (2021-01-01)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
by: Jonathan Feld, et al.
Published: (2021-04-01)

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
by: Stefano Molica, et al.
Published: (2021-06-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Guillain-Barre’-like Syndrome after Nelarabine Treatment
by: Ya-Ting Hsu, et al.
Published: (2014-09-01)

On the Origin of ETP Leukemias
by: Melania Tesio
Published: (2018-06-01)

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
by: Tong J, et al.
Published: (2021-07-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
by: Nil Albiol, et al.
Published: (2021-06-01)

Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia
by: Kelly M Reilly, et al.
Published: (2009-08-01)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
by: Sakshi Jasra, et al.
Published: (2021-01-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

Investigating the impact of ETP1 in Saccharomyces cerevisiae during Chardonnay fermentation
by: Hillier, Ashley Elizabeth
Published: (2013)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant? (Running Title: The Role of Salvage alloSCT in MM)
by: Hyunkyung Park, et al.
Published: (2020-07-01)

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia
by: Li-Ping Dou, et al.
Published: (2018-01-01)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
by: Judith Hecker, et al.
Published: (2018-07-01)

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report
by: Xuzhao Zhang, et al.
Published: (2021-07-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
by: Khadega A. Abuelgasim, et al.
Published: (2020-04-01)

Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL
by: L. Fransecky, et al.
Published: (2016-09-01)

Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation
by: Asu Fergun Yilmaz, et al.
Published: (2017-01-01)